

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

Application Number	10/582,184-Conf. #8960
--------------------	------------------------

Filing Date	September 26, 2007
-------------	--------------------

First Named Inventor	Lyon Bennabi
----------------------	--------------

Art Unit	1625
----------	------

Examiner Name	Patricia L. Morris
---------------	--------------------

Attorney Docket Number	BHC 031069 [83862(303989)]
------------------------	----------------------------

Sheet

1

of

2

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]Examiner
Signature

Date	
Considered	

* EXAMINER: Initial if reference considered whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(ii)) because that application was filed after June 30, 2003 or is available in the IFW. Applicant's unique citation designation number (applicant). ** Kind of Code of USPTO Patent Documents of www.uspto.gov or MPEP 901.04. * Enter Office that issued the patent document. * Enter date of issuance of the patent document. * Indicate the country or countries in which the invention has been granted by marking the box(es) in the column headed "Country". * Indicate the year of the grant of the patent by marking the box(es) in the column headed "Year". * Indicate the kind of document by marking the box(es) in the column headed "Kind of Document". * Indicate the symbol as indicated on the document under WIPO Standard ST. If it is possible. * Applicant is to place a check mark here if English language Translation is attached.

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being transmitted via the Office electronic filing system in accordance with § 1.6(a)(4).

Dated: November 5, 2009

Electronic Signature for Gabriel J. McCool: /Gabriel J. McCool/

Substitute for form 1449/PTO <h2 style="text-align: center; margin: 10px 0;">INFORMATION DISCLOSURE STATEMENT BY APPLICANT</h2> <p style="text-align: center; margin: 10px 0;"><i>(Use as many sheets as necessary)</i></p>		<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <th colspan="2" style="text-align: center; background-color: #f2f2f2;">Complete if Known</th> </tr> <tr> <td style="width: 30%;">Application Number</td> <td>10/582,184-Conf. #8960</td> </tr> <tr> <td>Filing Date</td> <td>September 26, 2007</td> </tr> <tr> <td>First Named Inventor</td> <td>Lyon Bennabi</td> </tr> <tr> <td>Art Unit</td> <td>1625</td> </tr> <tr> <td>Examiner Name</td> <td>Patricia L. Morris</td> </tr> <tr> <td>Attorney Docket Number</td> <td>BHC 031069 [83862(303989)]</td> </tr> </table>		Complete if Known		Application Number	10/582,184-Conf. #8960	Filing Date	September 26, 2007	First Named Inventor	Lyon Bennabi	Art Unit	1625	Examiner Name	Patricia L. Morris	Attorney Docket Number	BHC 031069 [83862(303989)]
Complete if Known																	
Application Number	10/582,184-Conf. #8960																
Filing Date	September 26, 2007																
First Named Inventor	Lyon Bennabi																
Art Unit	1625																
Examiner Name	Patricia L. Morris																
Attorney Docket Number	BHC 031069 [83862(303989)]																
Sheet	2	of	2														

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹
	CA	A. Somlyo et al.: "Cell Calcium and Its Regulation In Smooth Muscle," FASEB J. Vol. 3, 1989, pp. 2266-2276	
	CB	K. E. Kamm et al.: "The Function of Myosin and Myosin Light Chain Kinase Phosphorylation in Smooth Muscle," Am. Rev. Pharmacol. Toxicol., Vol. 25, 1985, pp. 593-620	
	CC	M. Noda et al.: "Involvement of rho in GTPγS-induced Enhancement of Phosphorylation of 20 kDa Myosin Light Chain in Vascular Smooth Muscle Cells: Inhibition of Phosphatase Activity," FEBS Letters, Vol 367, 1995, pp. 246-250	
	CD	M. Uehata et al.: "Calcium Sensitization of Smooth Muscle Mediated by a Rho-associated Protein Kinase in Hypertension," Nature, Vol. 389, October 30, 1997, pp. 990-994	
	CE	K. Itoh et al.: "An Essential Part for Rho-associated Kinase in the Transcellular Invasion of Tumor Cells," Nature Medicine, Vol. 5, No. 2, February 1999, pp. 221-225	
	CF	A. V. Somlyo et al.: "Rho-Kinase Inhibitor Retards Migration and <i>In Vivo</i> Dissemination of Human Prostate Cancer Cells," Biochemical and Biophysical Research Communications, Vol. 269, 2000, pp. 652-659	
	CG	D. Gingras et al.: "Tyrosine Phosphorylation of the Vascular Endothelial-Growth-Factor Receptor-2 (VEGFR-2) is Modulated by Rho Proteins," Biochem. J., Vol. 348, 2000, pp. 273-280	
	CH	S. Uchida et al.: "The Suppression of Small GTPase Rho Signal Transduction Pathway Inhibits Angiogenesis <i>In Vitro</i> and <i>In Vivo</i> ," Biochemical and Biophysical Research Communications, Vol. 269, 2000, pp. 633-640	

Examiner Signature	/David O Dell/	Date Considered	09/20/2010
--------------------	----------------	-----------------	------------

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

²Applicant's unique citation designation number (optional). ³Applicant is to place a check mark here if English language Translation is attached.